Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients
Menée aux Etats-Unis dans un contexte de vie réelle, cette étude analyse les nouvelles hospitalisations et les visites dans les services d'urgences hospitalières dans les 12 mois suivant l'administration d'une immunothérapie à base de lymphocytes CAR-T chez des patients atteints d'un cancer et bénéficiant d'une assurance médicale privée
Chimeric antigen receptor T (CAR) T-cell therapy has transformed the treatment of relapsed and refractory hematologic malignancies. However, this treatment carries notable toxicity risks, including cytokine release syndrome, neurologic complications, and infections, and potentially greater intensive health care use. Real-world data on health care use after hospital discharge from CAR T-cell infusion are lacking but are needed for risk-stratified disease management strategies. We examined rehospitalizations and emergency department (ED) visits during the first 12 months after hospitalization for CAR T-cell infusion among commercially insured patients.
JAMA Oncology 2022